Current indications for denosumab in benign bone tumours
EFORT Open Reviews, 2023 Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK–RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation. Given its high efficacy, denosumab
Antal Imre +2 more
doaj +1 more source
Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density : a randomized, double-blind, phase 2, parallel group study [PDF]
, 2018 Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532).
Binkley +17 more
core +2 more sources
Effects of RANKL-Targeted Therapy in Immunity and Cancer. [PDF]
, 2014 The role of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK system is well characterized within bone, where RANKL/RANK signaling mediates osteoclastogenesis and bone resorption.
Cheng, Michael L, Fong, Lawrence
core +2 more sources
Scientific Reports, 2023 Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, reduces skeletal-related events (SREs) and is approved for solid tumors with bone metastases.
Pei-An Fu +6 more
doaj +1 more source
Positioning novel biologicals in CKD-mineral and bone disorders [PDF]
, 2017 Renal osteodystrophy (ROD), the histologic bone lesions of chronic kidney disease (CKD), is now included in a wider syndrome with laboratory abnormalities of mineral metabolism and extra-skeletal calcifications or CKD-mineral and bone disorders (CKD-MBD),
Covic, Adrian +5 more
core +1 more source
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone [PDF]
, 2016 Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT.
Angelo Paolo Dei Tos +15 more
core +1 more source
Bone Reports, 2020 Discontinuation of denosumab is associated with the increase of bone turnover markers to above-baseline levels (so-called rebound in bone turnover) and rapid bone loss.
Masafumi Kashii +3 more
doaj +1 more source
Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report [PDF]
Cancer Rep (Hoboken)ABSTRACT Background Triple‐negative breast cancer (TNBC) with bone metastasis is associated with poor prognosis and limited treatment options. Denosumab has shown efficacy in preventing skeletal‐related events, while PARP inhibitors have demonstrated promising activity in patients with homologous recombination deficiency.
Liu L, Yu L, Wang Y, Zhang H, Zhang X.
europepmc +2 more sources
Recent Developments in Osteogenesis Imperfecta [PDF]
, 2015 Osteogenesis imperfecta (OI) is an uncommon genetic bone disease associated with brittle bones and fractures in children and adults. Although OI is most commonly associated with mutations of the genes for type I collagen, many other genes (some ...
Albert, Carolyne +3 more
core +2 more sources
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis [PDF]
Endocrinology and Metabolism, 2015 Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased ...
Yong-Ki Min
doaj +1 more source